Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $86.2 million.

  • Ligand Pharmaceuticals' Non Operating Income rose 100915.42% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 14602.49%. This contributed to the annual value of -$54.9 million for FY2024, which is 20618.74% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Non Operating Income stood at $86.2 million for Q3 2025, which was up 100915.42% from $2.8 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Non Operating Income's 5-year high stood at $110.5 million during Q1 2024, with a 5-year trough of -$109.6 million in Q4 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' median Non Operating Income value was $677000.0 (recorded in 2022), while the average stood at $3.7 million.
  • In the last 5 years, Ligand Pharmaceuticals' Non Operating Income plummeted by 234844.9% in 2023 and then soared by 100915.42% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Non Operating Income stood at -$19.8 million in 2021, then skyrocketed by 323.33% to $44.2 million in 2022, then plummeted by 53.76% to $20.5 million in 2023, then crashed by 635.83% to -$109.6 million in 2024, then surged by 178.65% to $86.2 million in 2025.
  • Its last three reported values are $86.2 million in Q3 2025, $2.8 million for Q2 2025, and -$14.0 million during Q1 2025.